Biodexa Pharmaceuticals PLC
BDRX
Company Profile
Business description
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Contact
1 Caspian Point
Caspian Way
CardiffCF10 4DQ
GBRT: +44 2920480180
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
13
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,880.60 | 49.30 | -0.55% |
| CAC 40 | 8,092.47 | 32.41 | -0.40% |
| DAX 40 | 24,025.23 | 204.68 | -0.84% |
| Dow JONES (US) | 48,209.34 | 207.22 | -0.43% |
| FTSE 100 | 9,657.74 | 93.57 | -0.96% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 22,986.12 | 71.29 | -0.31% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,424.95 | 16.81 | 0.13% |
| S&P 500 | 6,785.45 | 31.06 | -0.46% |
| S&P/ASX 200 | 8,598.90 | 48.40 | -0.56% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |